Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis Clinical research trials and Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis. Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis clinical trial. Human subjects often receive the most effective healthcare possible for their Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.

Home > "P" Clinical Trials Conditions > Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis

Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis



Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis

For Condition: Cytomegalovirus Retinitis,Acquired Immunodeficiency Syndrome
Status: Completed
Sponsor(s): National Center for Research Resources (NCRR) , Northwestern University
Synopsis: OBJECTIVES: I. Evaluate the safety and efficacy of intravenous cidofovir in patients with small peripheral cytomegalovirus retinitis. II. Obtain safety and efficacy data related to different dosages of cidofovir.
Details: PROTOCOL OUTLINE: This is a randomized study. Cidofovir is administered intravenously. Treatment ideally begins within 24 hours of randomization. In the first group, therapy is deferred until disease progression. Patients are then treated according to best medical judgement, which includes the option of cidofovir therapy. The second group receives induction with cidofovir every 7 days for 2 weeks, then begins maintenance with a low dose given every 14 days until dose-limiting toxicity or disease progression occurs. The third group receives the same cidofovir induction followed by a high maintenance dose given every 14 days until dose-limiting toxicity or disease progression occurs. Probenecid and intravenous hydration are administered concurrently with cidofovir. Patients are followed for progression and survival every 2 weeks for 23 weeks, then every 12 weeks. At disease progression, patients may be re-treated with another course of induction and maintenance.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 13 Years/60 Years
Genders: Both
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Acquired immunodeficiency syndrome (AIDS) Meets Centers for Disease Control and Prevention definition - Peripheral cytomegalovirus (CMV) retinitis Diagnosed by ophthalmologist certified by the Study of Ocular Complications of AIDS group At least 1 lesion measuring at least 25% of disc on photograph No lesion within zone 1 No lesion involving 25% or more of retina regardless of location - Visual acuity in affected eye 3 or more lines on the Early Treatment Diabetic Retinopathy Study chart at 1 meter Snellen equivalent 8/200 - No retinal detachment in affected eye - No media opacity that precludes visualization of fundus in both eyes - No extraocular CMV disease --Prior/Concurrent Therapy-- - No prior or concurrent anti-CMV therapy, i.e.: Ganciclovir Foscarnet CMV hyperimmune immunoglobulin Other investigational agents with anti-CMV activity - Prior CMV prophylaxis allowed - At least 7 days since nephrotoxic drugs, including: Amphotericin B Vidarabine Aminoglycoside antibiotics Intravenous pentamidine --Patient Characteristics-- - Age: 13 to 60 - Performance status: Karnofsky 60%-100% - Hematopoietic: ANC at least 750 Platelets at least 50,000 Hemoglobin greater than 7.5 g/dL - Hepatic: Bilirubin no greater than 3.0 mg/dL Transaminases no greater than 5 times normal - Renal: Creatinine no greater than 1.5 mg/dL Proteinuria less than 1+ No clinically significant renal disease No dialysis - Cardiovascular: No clinically significant cardiac disease, including: Ischemia Congestive heart failure Arrhythmia - Other: No probenecid allergy No medical problems sufficient to hinder compliance with therapy or follow- up, including drug or alcohol abuse No pregnant or nursing women Negative serum pregnancy test required of fertile women Adequate birth control required of fertile patients during and for 3 months after study
Total Enrollment: 90

Location and Contact Information:

Overall Study Official:
DavidWeinberg,  Study Chair,  Northwestern University


Additional Information:
Study ID Numbers:  199/11927;  NU-506
Study Start Date: March 1995
Record last reviewed: January 1998
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004794

Other Acquired Immunodeficiency Syndrome Studies:
1. The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients with AIDS

2. An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children

3. Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient

4. Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)

5. Immune Activity Against CVM Retinitis

Related Studies:

Other Acquired Immunodeficiency Syndrome Clinical Trials
Other Clinical Trials
Other Clinical Trials

Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis
Modify your Search

  Other Acquired Immunodeficiency Syndrome Clinical Trials
  Other Clinical Trials
  Other Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103